WOBURN, Mass., April 1, 2026
CanWell Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for CAN016, a dual-payload antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors, enabling the company to initiate a Phase I clinical trial. This milestone marks a significant step forward in advancing next-generation oncology therapeutics, particularly for patients who have progressed after prior ADC treatments, an area of high unmet medical need in cancer care.
FDA IND Clearance Enables First-in-Human Clinical Study
The FDA’s IND clearance allows CanWell Pharma to begin a Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics of CAN016, as well as to determine the recommended dose for future clinical development. The trial will enroll patients with HER2-positive solid tumors who have previously been treated with ADC therapies, focusing on a population that often develops resistance to existing treatments. This regulatory milestone underscores the successful completion of preclinical requirements, including toxicology, pharmacology, and Chemistry, Manufacturing, and Controls (CMC) data, demonstrating readiness for human clinical evaluation under strict GxP standards.
Dual-Payload ADC Design Targets Resistance Mechanisms
CAN016 represents a novel class of ADCs engineered with two distinct cytotoxic payloads within a single antibody construct, leveraging CanWell Pharma’s proprietary StarLinker platform. This innovative design enables synergistic anti-tumor activity by combining complementary mechanisms of action, addressing a key limitation of traditional single-payload ADCs, which often encounter resistance over time. In preclinical studies, CAN016 demonstrated potent anti-tumor efficacy across multiple CDX and PDX models, including those resistant to currently approved HER2-targeted therapies.
Advertisement
The therapy works by delivering dual cytotoxic agents directly into tumor cells, resulting in enhanced tumor cell killing, inhibition of proliferation, and induction of apoptosis. This breakthrough approach positions CAN016 as a promising candidate in overcoming resistance in advanced oncology treatment.
Advancing Oncology Innovation Under GxP Frameworks
The development of CAN016 reflects strong adherence to Good Laboratory Practice (GLP) in preclinical studies, Good Manufacturing Practice (GMP) for the production of complex biologic conjugates, and Good Clinical Practice (GCP) as the program enters clinical trials. ADCs are among the most technically complex biologics, requiring precise linker stability, payload conjugation, and quality control processes to ensure safety and efficacy.
CanWell Pharma’s IND clearance demonstrates regulatory confidence in its manufacturing and development capabilities, as well as its ability to meet stringent FDA requirements. The initiation of Phase I trials will be critical in validating CAN016’s safety profile and clinical potential, paving the way for subsequent studies and potential regulatory submissions.
Strategic Impact on the Oncology Therapeutics Landscape
The global oncology market continues to expand rapidly, driven by demand for targeted therapies capable of addressing treatment resistance and improving patient outcomes. HER2-positive cancers remain a key focus area, with ongoing innovation in biologics and precision medicine approaches. CAN016’s dual-payload ADC design introduces a new paradigm in cancer treatment, offering the potential to enhance efficacy while overcoming limitations of existing therapies.
This advancement reinforces CanWell Pharma’s position as an emerging leader in ADC innovation, with a pipeline focused on delivering first-in-class and best-in-class oncology solutions. As the Phase I trial progresses, the company aims to generate clinical data that could support accelerated development pathways and future regulatory approvals, contributing to the evolution of next-generation cancer therapeutics.
Source: CanWell Pharma press release
